BACKGROUND AND PURPOSE: Matrix metalloproteinases (MMPs) have been implicated in joint tissue destruction in arthritis. However, MMPs have not been assigned a role in joint pain. We investigated the ability of BaP1, a metalloproteinase from Bothrops asper snake venom, with structural homology to MMPs, to induce joint hypernociception. EXPERIMENTAL APPROACH: Animals received intra-articular (i.art.) BaP1. Hypernociception was assessed using the rat-knee joint articular incapacitation test. Cell influx, prostaglandin E(2) (PGE(2)), and TNF-alpha levels were assessed in joint exudates following BaP1 injection. KEY RESULTS: BaP1 (5 microg per joint) provoked hypernociception between 1 and 6 h after i.art. injection. Cell influx, mostly neutrophils, was maximal 3 h after BaP1 i.art. injection. BaP1 also led to increase in PGE(2) and TNF-alpha levels in the joint exudates. Pretreatment with either indomethacin (4 mg.kg(-1) i.p.) or with an anti-TNF-alpha antiserum (i.art.) significantly inhibited both BaP1-induced joint hypernociception and cell influx. In isolated rat peritoneal macrophages, BaP1 increased cyclooxygenase (COX)-2 expression, while not altering that of COX-1. CONCLUSIONS AND IMPLICATIONS: This is the first demonstration that a metalloproteinase promotes joint hypernociception. This effect involves local release of PGE(2) and TNF-alpha. BaP1-induced increase in PGE(2) is associated to increased COX-2 expression in macrophages. Blocking PGE(2) or TNF-alpha inhibits BaP1-induced hypernociception. In addition to unravelling a hitherto unknown mechanism whereby TNF blockade provides analgesia in arthritis, the data show, for the first time that MMPs are involved in inflammatory joint hypernociception and induce COX-2 expression.
BACKGROUND AND PURPOSE: Matrix metalloproteinases (MMPs) have been implicated in joint tissue destruction in arthritis. However, MMPs have not been assigned a role in joint pain. We investigated the ability of BaP1, a metalloproteinase from Bothrops asper snake venom, with structural homology to MMPs, to induce joint hypernociception. EXPERIMENTAL APPROACH: Animals received intra-articular (i.art.) BaP1. Hypernociception was assessed using the rat-knee joint articular incapacitation test. Cell influx, prostaglandin E(2) (PGE(2)), and TNF-alpha levels were assessed in joint exudates following BaP1 injection. KEY RESULTS:BaP1 (5 microg per joint) provoked hypernociception between 1 and 6 h after i.art. injection. Cell influx, mostly neutrophils, was maximal 3 h after BaP1 i.art. injection. BaP1 also led to increase in PGE(2) and TNF-alpha levels in the joint exudates. Pretreatment with either indomethacin (4 mg.kg(-1) i.p.) or with an anti-TNF-alpha antiserum (i.art.) significantly inhibited both BaP1-induced joint hypernociception and cell influx. In isolated rat peritoneal macrophages, BaP1 increased cyclooxygenase (COX)-2 expression, while not altering that of COX-1. CONCLUSIONS AND IMPLICATIONS: This is the first demonstration that a metalloproteinase promotes joint hypernociception. This effect involves local release of PGE(2) and TNF-alpha. BaP1-induced increase in PGE(2) is associated to increased COX-2 expression in macrophages. Blocking PGE(2) or TNF-alpha inhibits BaP1-induced hypernociception. In addition to unravelling a hitherto unknown mechanism whereby TNF blockade provides analgesia in arthritis, the data show, for the first time that MMPs are involved in inflammatory joint hypernociception and induce COX-2 expression.
Authors: Cristina Maria Fernandes; Stella Regina Zamuner; Juliana Pavan Zuliani; Alexandra Rucavado; José Maria Gutiérrez; Catarina de Fátima Pereira Teixeira Journal: Toxicon Date: 2006-03-10 Impact factor: 3.033
Authors: R A Black; C T Rauch; C J Kozlosky; J J Peschon; J L Slack; M F Wolfson; B J Castner; K L Stocking; P Reddy; S Srinivasan; N Nelson; N Boiani; K A Schooley; M Gerhart; R Davis; J N Fitzner; R S Johnson; R J Paxton; C J March; D P Cerretti Journal: Nature Date: 1997-02-20 Impact factor: 49.962
Authors: R Maini; E W St Clair; F Breedveld; D Furst; J Kalden; M Weisman; J Smolen; P Emery; G Harriman; M Feldmann; P Lipsky Journal: Lancet Date: 1999-12-04 Impact factor: 79.321
Authors: R S Talhouk; L Hajjar; R Abou-Gergi; C J Simaa'n; G Mouneimne; N E Saade'; B Safieh-Garabedian Journal: Pain Date: 2000-02 Impact factor: 6.961
Authors: José María Gutiérrez; Teresa Escalante; Alexandra Rucavado; Cristina Herrera; Jay W Fox Journal: Toxins (Basel) Date: 2016-10-22 Impact factor: 4.546
Authors: Marcela C S Silva; Soraya S Pereira; Marilia P Gouveia; Marcos B Luiz; Rosa M O Sousa; Anderson M Kayano; Aleff F Francisco; Nidiane D R Prado; Leandro S M Dill; Marcos R M Fontes; Fernando B Zanchi; Rodrigo G Stabeli; Andreimar M Soares; Juliana P Zuliani; Carla F C Fernandes Journal: Biomed Res Int Date: 2022-07-19 Impact factor: 3.246
Authors: Ji Eun Yu; In Jun Yeo; Dong Won Lee; Ju Young Chang; Dong Ju Son; Jaesuk Yun; Sang-Bae Han; Jin Tae Hong Journal: J Cancer Date: 2022-09-21 Impact factor: 4.478
Authors: Mariana N Viana; Elbio Leiguez; José M Gutiérrez; Alexandra Rucavado; Regina P Markus; Marina Marçola; Catarina Teixeira; Cristina M Fernandes Journal: Sci Rep Date: 2020-02-24 Impact factor: 4.379